Patents by Inventor Joshua Syken

Joshua Syken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10766869
    Abstract: The invention relates to triazole compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: September 8, 2020
    Assignee: VERTEX PHARMACEUTCALS INCORPORATED
    Inventors: Robert J. Davies, Jingrong Cao, Meghan Elise Cockerill, Philip Noel Collier, Elisabeth Doyle, James Daniel Frantz, Huai Gao, Brian Anthony Goldman, Ronald Lee Grey, Jr., Anne-Laure Grillot, Wenxin Gu, James A. Henderson, Raul Eduardo Krauss, Adrianne Lynn Kolpak, Yusheng Liao, Sanjay Shivayogi Magavi, David Messersmith, Albert Charles Pierce, Emanuele Perola, Elizabeth Jin-Sun Ryu, Joshua Syken, Jian Wang, Michael Paul DeNinno, Francois Maltais
  • Publication number: 20190185436
    Abstract: The invention relates to triazole compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.
    Type: Application
    Filed: October 17, 2018
    Publication date: June 20, 2019
    Inventors: Robert J. Davies, Jingrong Cao, Meghan Elise Cockerill, Philip Noel Collier, Elisabeth Doyle, James Daniel Frantz, Huai Gao, Brian Anthony Goldman, Ronald Lee Grey, JR., Anne-Laure Grillot, Wenxin Gu, James A. Henderson, Raul Eduardo Krauss, Adrianne Lynn Kolpak, Yusheng Liao, Sanjay Shivayogi Magavi, David Messersmith, Albert Charles Pierce, Emanuele Perola, Elizabeth Jin-Sun Ryu, Joshua Syken, Jian Wang, Michael Paul DeNinno, Francois Maltais
  • Patent number: 10118904
    Abstract: The invention relates to triazole compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: November 6, 2018
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Robert J. Davies, Jingrong Cao, Meghan Elise Cockerill, Philip Noel Collier, Elisabeth Doyle, James Daniel Frantz, Huai Gao, Brian Anthony Goldman, Ronald Lee Grey, Jr., Anne-Laure Grillot, Wenxin Gu, James A. Henderson, Raul Eduardo Krauss Irarrazaval, Adrianne Lynn Kolpak, Yusheng Liao, Sanjay Shivayogi Magavi, David Messersmith, Albert Charles Pierce, Emanuele Perola, Elizabeth Jin-Sun Ryu, Joshua Syken, Jian Wang, Michael Paul DeNinno, Francois Maltais
  • Publication number: 20160355488
    Abstract: The invention relates to triazole compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.
    Type: Application
    Filed: June 3, 2016
    Publication date: December 8, 2016
    Inventors: Robert J. Davies, Jingrong Cao, Meghan Elise Cockerill, Philip Noel Collier, Elisabeth Doyle, James Daniel Frantz, Huai Gao, Brian Anthony Goldman, Ronald Lee Grey, Jr., Anne-Laure Grillot, Wenxin Gu, James A. Henderson, Raul Eduardo Krauss Irarrazaval, Adrianne Lynn Kolpak, Yusheng Liao, Sanjay Shivayogi Magavi, David Messersmith, Albert Charles Pierce, Emanuele Perola, Elizabeth Jin-Sun Ryu, Joshua Syken, Jian Wang, Michael Paul DeNinno, Francois Maltais
  • Patent number: 8071314
    Abstract: Class I major histocompatibility complex, is required in the activity-dependent refinement and plasticity of connections in the developing and adult central nervous system, demonstrating that molecules can perform critical roles in both systems. Similarities in the cellular signaling mechanisms of the immune and nervous systems provide for development of therapeutic and diagnostic agents in abnormal neuronal cellular function.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: December 6, 2011
    Assignee: President and Fellows of Harvard College
    Inventors: Carla J. Shatz, Joshua Syken
  • Publication number: 20090098109
    Abstract: The present invention relates PirB expression and function in nervous tissue. PirB expressed in neurons acts to restrict plasticity of neural circuits, and/or, restrict competition between circuits with different activity patterns or levels, for cortical representation. Thus, the present invention relates to methods of increasing nervous system plasticity and associated disorders and diseases in a subject comprising administering to the subject an agent which modulates the activity, signal transduction or expression of PirB in neurons of the subject.
    Type: Application
    Filed: January 23, 2007
    Publication date: April 16, 2009
    Applicant: President and Fellows of Harvard College
    Inventors: Carla Shatz, Joshua Syken
  • Patent number: 6825005
    Abstract: The invention provides isolated nucleic acids and vectors encoding two splice forms of Tid1 (Tid-1L and Tid-1S) and cells and non-human organisms comprising such. The invention further provides methods for modulating apoptosis in a cell by modulating the amount and/or activity of these two splice forms relative to each other. Such methods can be used in vivo and in vitro, e.g., in cell cultures, for either making cells more susceptible to apotosis or more resistant to it.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: November 30, 2004
    Assignee: President and Fellows of Harvard College
    Inventors: Joshua Syken, Karl Münger
  • Publication number: 20030170690
    Abstract: Class I major histocompatibility complex, is required in the activity-dependent refinement and plasticity of connections in the developing and adult central nervous system, demonstrating that molecules can perform critical roles in both systems. Similarities in the cellular signaling mechanisms of the immune and nervous systems provide for development of therapeutic and diagnostic agents in abnormal neuronal cellular function.
    Type: Application
    Filed: December 16, 2002
    Publication date: September 11, 2003
    Inventors: Carla J. Shatz, Joshua Syken
  • Publication number: 20020086844
    Abstract: The invention provides isolated nucleic acids and vectors encoding two splice forms of Tid1 (Tid-1L and Tid-1S) and cells and non-human organisms comprising such. The invention further provides methods for modulating apoptosis in a cell by modulating the amount and/or activity of these two splice forms relative to each other. Such methods can be used in vivo and in vitro, e.g., in cell cultures, for either making cells more susceptible to apotosis or more resistant to it.
    Type: Application
    Filed: July 19, 2001
    Publication date: July 4, 2002
    Inventors: Joshua Syken, Karl Munger